Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
About the study
Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy.
- Progressed or was intolerant to all available therapies known to confer clinical benefit appropriate for their tumor type for which the patient was eligible and willing to receive.
- Adequate bone marrow, kidney and liver function
- Performance status of 0 or 1.
- Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement.
EXCLUSION CRITERIA
Exclusion Criteria:
• Prior treatment targeting LAIR1
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Melanoma,Pancreatic Cancer,Breast Cancer,Gastric Cancer,Non Small Cell Lung Cancer,Cervical Cancer,Endocervical Cancer,Squamous Cell Carcinoma of Head and Neck,Bladder Urothelial Cancer,Colorectal Cancer,Esophageal Cancer,Ovarian Cancer,Renal Cell Carcinoma,Prostate Cancer,Mesothelioma,Cholangiocarcinoma
Age (in years)
18+
Phase
Phase 1
Participants needed
71
Est. Completion Date
Jun 30, 2024
Treatment type
Interventional
Sponsor
NGM Biopharmaceuticals, Inc
ClinicalTrials.gov identifier
NCT05311618
Study number
438-IO-101
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?